LeserbriefKommentar
PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer
New England Journal of Medicine · 05.11.2026 · 395 (18) · 1872-1875
DOI: 10.1056/nejmc2611171 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 05.11.2026. Verfasst von Neeraj Agarwal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Boston. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Dana-Farber Cancer Institute, Boston.
- National Cancer Center Hospital East, Chiba, Japan.
- Centre Oscar Lambret, Lille, France.
Zitieren
APA
Agarwal, N., Matsubara, N., & Fizazi, K. (2026). PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer. New England Journal of Medicine, 395(18), 1872-1875. https://doi.org/10.1056/nejmc2611171
Vancouver
Agarwal N, Matsubara N, Fizazi K. PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer. New England Journal of Medicine. 2026;395(18):1872-1875. doi:10.1056/nejmc2611171
BibTeX
@article{Agarwal2026,
author = {Agarwal, Neeraj and Matsubara, Nobuaki and Fizazi, Karim},
title = {PARP and Androgen-Signaling Inhibition in Metastatic Prostate Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {18},
pages = {1872--1875},
doi = {10.1056/nejmc2611171}
}
EUVIMED